Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein.
about
c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's diseaseDisrupted autophagy leads to dopaminergic axon and dendrite degeneration and promotes presynaptic accumulation of α-synuclein and LRRK2 in the brainA blood-brain barrier (BBB) disrupter is also a potent α-synuclein (α-syn) aggregation inhibitor: a novel dual mechanism of mannitol for the treatment of Parkinson disease (PD)Mechanisms of rotenone-induced proteasome inhibitionGait dynamics in mouse models of Parkinson's disease and Huntington's disease.Mitochondria: A Therapeutic Target for Parkinson's Disease?Genetically engineered mouse models of Parkinson's diseaseA progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") miceMitochondrial dysfunction and oxidative stress in Parkinson's diseaseIncreased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits.Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson's disease.Circadian dysfunction may be a key component of the non-motor symptoms of Parkinson's disease: insights from a transgenic mouse modelSex Differences in Circadian Dysfunction in the BACHD Mouse Model of Huntington's DiseaseNeuroprotective activities of palmitoylethanolamide in an animal model of Parkinson's diseaseAge-dependent motor deficits and dopaminergic dysfunction in DJ-1 null miceDysregulated striatal neuronal processing and impaired motor behavior in mice lacking huntingtin interacting protein 14 (HIP14)Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019SGlucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson's disease.Evidence for early and progressive ultrasonic vocalization and oromotor deficits in a PINK1 gene knockout rat model of Parkinson's diseaseVocal training, levodopa, and environment effects on ultrasonic vocalizations in a rat neurotoxin model of Parkinson disease.Vocalization deficits in mice over-expressing alpha-synuclein, a model of pre-manifest Parkinson's disease.The Sex Chromosome Trisomy mouse model of XXY and XYY: metabolism and motor performance.Norepinephrine loss produces more profound motor deficits than MPTP treatment in miceProgressive behavioral deficits in DJ-1-deficient mice are associated with normal nigrostriatal function.Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease.Gamma-synucleinopathy: neurodegeneration associated with overexpression of the mouse protein.RGS4 is required for dopaminergic control of striatal LTD and susceptibility to parkinsonian motor deficitsSensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson's disease.Time course and progression of wild type α-synuclein accumulation in a transgenic mouse model.Genetic mouse models of parkinsonism: strengths and limitations.Parallel dopamine D1 receptor activity dependence of l-Dopa-induced normal movement and dyskinesia in mice.Axon degeneration and PGC-1α-mediated protection in a zebrafish model of α-synuclein toxicityNext-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.Late-stage α-synuclein accumulation in TNWT-61 mouse model of Parkinson's disease detected by diffusion kurtosis imaging.Motor deficits and altered striatal gene expression in aphakia (ak) mice.Strengths and limitations of genetic mouse models of Parkinson's disease.Modulation of alpha-synuclein expression in transgenic animals for modelling synucleinopathies--is the juice worth the squeeze?Restorative effect of endurance exercise on behavioral deficits in the chronic mouse model of Parkinson's disease with severe neurodegeneration.Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein.Context dependent neuroprotective properties of prion protein (PrP).
P2860
Q24318974-71C9FDDA-FD77-4CE2-BE1A-C4B6D722B7D7Q24599233-C503B3B4-BBF5-4B4D-8913-A373E4473654Q24612655-14BD4E7F-2862-4B20-9A1F-45EE5C4068F6Q24633912-3C606A75-F3A2-4A74-9ACF-45BE4F19C37CQ24812417-BA09CDA1-11A3-49B4-B710-7EE477697082Q26784216-897CAE0C-A4EF-46BF-9728-8835E0A6C2C5Q26852964-00E65090-C2F9-4151-A47B-A114782A3D35Q26859072-00F71AD0-337E-464D-8DD1-81A885FE8F64Q27014051-00F5FDB7-8B9E-405C-A7CA-B952E1C4910BQ27308109-A9678A24-8B5C-474A-BF0E-5B42DA1E9D4BQ27310355-E5CC2C0E-F373-43CD-814F-780091D6914FQ28384426-27A4CBC5-288C-4197-B124-8BD928F27765Q28386809-D5C4F70A-12FA-4337-8388-50F517549FA8Q28482356-A7C7C2E9-9FC7-4E2E-B033-B0DE99AE7B67Q28507691-D92E118E-072C-447B-BD8C-7017A4D1A3BCQ28537948-782B663E-F4E0-40E9-B479-EC38DEFAB6B2Q28589899-BA5ABF3F-47BE-4907-8498-971C5EAD4A43Q30367337-EB62DC3B-E93E-490A-BB23-C4ECFBB3F01CQ30371129-397C28F9-A255-4385-9474-97728D13AC23Q30380046-092BFD3C-A504-4954-9D38-893FBF8681A0Q30415147-9101BCE4-F862-43AA-9BAF-C26F0022BF47Q30417573-21422F49-14B3-4EC2-963B-343285577165Q30479999-7F131589-CEF4-4EAF-93C2-4A0CC2CBCEC4Q30481530-E1F2FF87-499A-4C51-97D6-308901203759Q30484170-8341870F-8F6F-4880-BE55-D94E54DD833AQ30487162-7EC29EDA-E592-4056-AD37-752C140B2520Q30504550-E038924F-69BE-4524-9986-444811113FC7Q30512976-BFD4528E-5341-433F-8CA7-D849C3A375D1Q30532478-04A43318-21A0-4634-B00F-D294650C54E2Q30537732-462D4320-C7BC-4FE3-9037-42458D211251Q30538394-F81692E5-38EA-475E-8B8B-A1917FAD0667Q30577415-2D85D9A7-4403-48C7-B2E4-D91D10663167Q30578913-C1D350D4-67F5-4EF9-9139-C11817CE4CE6Q31032932-83B7DFC0-8058-4A77-BFE0-512EF30572A6Q33303267-8252AA9C-2220-490B-9195-ADE4D8E2A45BQ33347250-7DB3FF23-1EB4-4F94-9369-B4B7AE44CD36Q33392127-D2E428FC-0482-40F6-8161-5C82FD7DE520Q33401101-7CD1906D-98E8-4734-AEDF-A24A2128DBD7Q33577056-A9DF2CA1-0A06-4E1A-9C9B-1F5F9435ABF3Q33595425-1E248402-51D2-40E3-81A5-75E2D54DCE54
P2860
Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Early and progressive sensorim ...... ld-type human alpha-synuclein.
@en
Early and progressive sensorim ...... ld-type human alpha-synuclein.
@nl
type
label
Early and progressive sensorim ...... ld-type human alpha-synuclein.
@en
Early and progressive sensorim ...... ld-type human alpha-synuclein.
@nl
prefLabel
Early and progressive sensorim ...... ld-type human alpha-synuclein.
@en
Early and progressive sensorim ...... ld-type human alpha-synuclein.
@nl
P2093
P1476
Early and progressive sensorim ...... ild-type human alpha-synuclein
@en
P2093
Edward Rockenstein
Eliezer Masliah
Jonathan Salcedo
Marie-Françoise Chesselet
Michael S Levine
Sheila M Fleming
P304
P356
10.1523/JNEUROSCI.3080-04.2004
P407
P577
2004-10-01T00:00:00Z